NCT03535350View on ClinicalTrials.gov

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 24, 2018

Primary Completion Date

April 4, 2023

Study Completion Date

December 30, 2025

Conditions
Glioblastoma
Interventions
DRUG

Ibrutinib

"Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2."

RADIATION

Radiation

2Gy x 30minutes for 6 weeks.

DRUG

Temozolomide (TMZ)

Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER